A critique of emerging European legislation in the pharmaceutical industry: A clinical trials analysis

Elizabeth Murray; Rodney McAdam; Moira T. Burke

doi:10.1108/09526860410563195

A critique of emerging European legislation in the pharmaceutical industry: A clinical trials analysis

Elizabeth Murray, Rodney McAdam, Moira T. Burke

Research output: Contribution to journal › Article › peer-review

1 Citation (Scopus)

Abstract

The objective of this paper is to critique emerging legislation in the pharmaceutical industry, focusing on the clinical trials sector. Possible changes are identified and discussed in relation to their impact on phase I clinical trials conducted in the UK. It is concluded that smaller contract research organisations, which have benefited in the past from European Union legislative variation, may have resource problems in trying to cope with the changing business environment created through legislative harmonization. These SMEs must use this opportunity to seek clinical trials research partnerships in a new harmonized EU market.

Original language	English
Pages (from-to)	389-393
Number of pages	5
Journal	International Journal of Health Care Quality Assurance
Volume	17
Issue number	7
DOIs	https://doi.org/10.1108/09526860410563195
Publication status	Published (in print/issue) - 2004

Bibliographical note

Copyright:
Copyright 2010 Elsevier B.V., All rights reserved.

Keywords

Clinical medicine
European union information
Organizational change
Pharmaceuticals industry
Research organizations

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1108/09526860410563195

Cite this

@article{7f864598c5e847bdbe7b3225a1e49ea5,

title = "A critique of emerging European legislation in the pharmaceutical industry: A clinical trials analysis",

abstract = "The objective of this paper is to critique emerging legislation in the pharmaceutical industry, focusing on the clinical trials sector. Possible changes are identified and discussed in relation to their impact on phase I clinical trials conducted in the UK. It is concluded that smaller contract research organisations, which have benefited in the past from European Union legislative variation, may have resource problems in trying to cope with the changing business environment created through legislative harmonization. These SMEs must use this opportunity to seek clinical trials research partnerships in a new harmonized EU market.",

keywords = "Clinical medicine, European union information, Organizational change, Pharmaceuticals industry, Research organizations",

author = "Elizabeth Murray and Rodney McAdam and Burke, {Moira T.}",

year = "2004",

doi = "10.1108/09526860410563195",

language = "English",

volume = "17",

pages = "389--393",

journal = "International Journal of Health Care Quality Assurance",

issn = "0952-6862",

publisher = "Emerald Publishing",

number = "7",

}

TY - JOUR

T1 - A critique of emerging European legislation in the pharmaceutical industry

T2 - A clinical trials analysis

AU - Murray, Elizabeth

AU - McAdam, Rodney

AU - Burke, Moira T.

PY - 2004

Y1 - 2004

N2 - The objective of this paper is to critique emerging legislation in the pharmaceutical industry, focusing on the clinical trials sector. Possible changes are identified and discussed in relation to their impact on phase I clinical trials conducted in the UK. It is concluded that smaller contract research organisations, which have benefited in the past from European Union legislative variation, may have resource problems in trying to cope with the changing business environment created through legislative harmonization. These SMEs must use this opportunity to seek clinical trials research partnerships in a new harmonized EU market.

AB - The objective of this paper is to critique emerging legislation in the pharmaceutical industry, focusing on the clinical trials sector. Possible changes are identified and discussed in relation to their impact on phase I clinical trials conducted in the UK. It is concluded that smaller contract research organisations, which have benefited in the past from European Union legislative variation, may have resource problems in trying to cope with the changing business environment created through legislative harmonization. These SMEs must use this opportunity to seek clinical trials research partnerships in a new harmonized EU market.

KW - Clinical medicine

KW - European union information

KW - Organizational change

KW - Pharmaceuticals industry

KW - Research organizations

UR - http://www.scopus.com/inward/record.url?scp=16544369138&partnerID=8YFLogxK

U2 - 10.1108/09526860410563195

DO - 10.1108/09526860410563195

M3 - Article

C2 - 15552394

AN - SCOPUS:16544369138

SN - 0952-6862

VL - 17

SP - 389

EP - 393

JO - International Journal of Health Care Quality Assurance

JF - International Journal of Health Care Quality Assurance

IS - 7

ER -

A critique of emerging European legislation in the pharmaceutical industry: A clinical trials analysis

Abstract

Bibliographical note

Keywords

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this